AMENDED AND RESTATED COLLABORATION, LICENSE AND OPTION AGREEMENT by and between ACCELERON PHARMA, INC. and CELGENE CORPORATIONCollaboration, License and Option Agreement • November 7th, 2017 • Acceleron Pharma Inc • Biological products, (no disgnostic substances) • New York
This Amended and Restated Collaboration, License and Option Agreement (this “Agreement” and, as the context requires, this “Agreement” shall mean this Agreement or the Amended Agreement) dated the 18th day of September, 2017 (the “Amended and Restated Effective Date”) is by and between Acceleron Pharma, Inc., a Delaware corporation having its principal office at 149 Sidney Street, Cambridge, MA 02139 (“Acceleron”) and Celgene Corporation, a Delaware corporation having its principal office at 86 Morris Avenue, Summit, NJ 07901 (“Celgene”). Acceleron and Celgene may each be referred to herein individually as a “Party” and collectively as the “Parties.”
